Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Susceptibility-guided vs Empiric Therapy for Rescue Treatment of H. Pylori Infection
NCT05332444Phase 4Recruiting
- Sponsor
- National Taiwan University Hospital
- Start
- Apr 2022
- Primary completion
- Dec 2026
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 4 trial of rabeprazole, amoxicillin, clarithromycin, levofloxacin, metronidazole in Helicobacter pylori infection, sponsored by National Taiwan University Hospital. Started Apr 2022; status: recruiting.
02
Drugs
rabeprazoleamoxicillinclarithromycinlevofloxacinmetronidazole
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT05332444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05332444.